Characterization of inhibitory anti-duffy binding protein II immunity: Approach to plasmodium vivax vaccine development in Thailand

Simple item page
dc.contributor.authorPatchanee Chootong
dc.contributor.authorTasanee Panichakul
dc.contributor.authorChongrak Permmongkol
dc.contributor.authorSamantha J. Barnes
dc.contributor.authorRachanee Udomsangpetch
dc.contributor.authorJohn H. Adams
dc.contributor.correspondenceP. Chootong; Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand; email: pchooton@gmail.com
dc.date.accessioned2025-03-10T07:37:40Z
dc.date.available2025-03-10T07:37:40Z
dc.date.issued2012
dc.description.abstractPlasmodium vivax Duffy binding protein region II (DBPII) is an important vaccine candidate for antibody-mediated immunity against vivax malaria. A significant challenge for vaccine development of DBPII is its highly polymorphic nature that alters sensitivity to neutralizing antibody responses. Here, we aim to characterize naturally-acquired neutralizing antibodies against DBPII in individual Thai residents to give insight into P. vivax vaccine development in Thailand. Anti-DBPII IgG significantly increased in acute vivax infections compared to uninfected residents and naive controls. Antibody titers and functional anti-DBPII inhibition varied widely and there was no association between titer and inhibition activity. Most high titer plasmas had only a moderate to no functional inhibitory effect on DBP binding to erythrocytes, indicating the protective immunity against DBPII binding is strain specific. Only 5 of 54 samples were highly inhibitory against DBP erythrocyte-binding function. Previously identified target epitopes of inhibitory anti-DBPPII IgG (H1, H2 and H3) were localized to the dimer interface that forms the DARC binding pocket. Amino acid polymorphisms (monomorphic or dimorphic) in H1 and H3 protective epitopes change sensitivity of immune inhibition by alteration of neutralizing antibody recognition. The present study indicates Thai variant H1.T1 (R308S), H3.T1 (D384G) and H3.T3 (K386N) are the most important variants for a DBPII candidate vaccine needed to protect P. vivax in Thai residents. © 2012 Chootong et al.
dc.identifier.citationPLoS ONE
dc.identifier.doi10.1371/journal.pone.0035769
dc.identifier.issn19326203
dc.identifier.scopus2-s2.0-84860482942
dc.identifier.urihttps://repository.dusit.ac.th//handle/123456789/4997
dc.languageEnglish
dc.rightsAll Open Access; Gold Open Access; Green Open Access
dc.rights.holderScopus
dc.titleCharacterization of inhibitory anti-duffy binding protein II immunity: Approach to plasmodium vivax vaccine development in Thailand
dc.typeArticle
mods.location.urlhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84860482942&doi=10.1371%2fjournal.pone.0035769&partnerID=40&md5=5492fc76a7a2610b95377db889275d46
oaire.citation.issue4
oaire.citation.volume7
Files
Collections
SCOPUS 2010-2014